RecruitingPhase 3NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
Beachwood, OH · Canton, OH · Cincinnati, OH · +137 more sites